Press Releases

Repertoire Immune Medicines Receives Funding From COVID-19 High Performance Computing Consortium
CAMBRIDGE, Mass. – June 24, 2020 – Repertoire Immune Medicines, a clinical-stage biotech company tooled to decode and deploy the immune system across multiple major diseases, today announced that it has received funding from the COVID-19 High Performance Computing (HPC) Consortium, a private-public sector effort offering computing capabilities to support COVID-19 research programs. Repertoire’s research project aims to identify viral epitopes most likely to induce durable immunity to SARS-CoV-2, the virus that causes COVID-19, through induction of long-term memory in T cells. Under this grant, Repertoire will leverage the cloud computing resources of Amazon Web Service (AWS) to simulate and predict the complex immunological interactions across patient populations that lead to clearance of SARS-CoV-2.
Download
Repertoire Immune Medicines Receives Funding From COVID-19 High Performance Computing Consortium
CAMBRIDGE, Mass. – June 24, 2020 – Repertoire Immune Medicines, a clinical-stage biotech company tooled to decode and deploy the immune system across multiple major diseases, today announced that it has received funding from the COVID-19 High Performance Computing (HPC) Consortium, a private-public sector effort offering computing capabilities to support COVID-19 research programs. Repertoire’s research project aims to identify viral epitopes most likely to induce durable immunity to SARS-CoV-2, the virus that causes COVID-19, through induction of long-term memory in T cells. Under this grant, Repertoire will leverage the cloud computing resources of Amazon Web Service (AWS) to simulate and predict the complex immunological interactions across patient populations that lead to clearance of SARS-CoV-2.
Download
Repertoire Immune Medicines Strengthens Executive Team; Names Biotech Industry Veterans to Key Roles
CAMBRIDGE, Mass. – April 23, 2020 – Repertoire Immune Medicines, a clinical-stage biotech company working to unleash the curative power of the immune system, today announced the addition of three new members to its executive team: Andrea DiFabio, EVP, Chief Legal and Corporate Administration Officer; Tim Harris, Ph.D., Dsc., EVP, Corporate Development and Lucia Celona, EVP, Chief Human Resources Officer.
Download
Repertoire Immune Medicines Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund
CAMBRIDGE AND BOSTON, MA – March 25, 2020 – Repertoire Immune Medicines, a newly launched company working to unleash the curative power of the immune system to prevent and cure disease, today announced an investment from the JDRF T1D Fund, a venture philanthropy vehicle focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D).
Download
Flagship Pioneering Announces the Launch of Repertoire Immune Medicines with Industry Veteran John G. Cox as Chief Executive Officer
Cambridge, MA, March 12, 2020 – Flagship Pioneering, a life sciences innovation enterprise, announced the launch of Repertoire Immune Medicines, a clinical-stage biotechnology company tapping the curative powers of our immune system to prevent, treat and cure cancer, autoimmune disorders and infectious diseases.
Download